文献速递认知障碍与痴呆

利用血浆生物标志物检测唐氏综合征脑tau蛋白病理

Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers.
PubMed 文献 · JAMA Neurol · 2022-01-01

该横断面多中心研究纳入300例唐氏综合征成人及37例非唐氏综合征同胞对照,评估血浆p-tau217等标志物检测tau-PET异常的能力。结果显示血浆p-tau217联合年龄检测颞叶和新皮质tau-PET异常的AUC为0.96-0.99,且p-tau217与DS精神状况检查和线索回忆测试表现较差相关。

要点

  • 血浆p-tau217联合年龄检测唐氏综合征tau-PET异常的AUC达0.96-0.99。
  • p-tau217和GFAP与异常tau-PET及Aβ-PET状态持续相关(OR范围1.59-2.32)。
  • 较高p-tau217水平与DS精神状况检查(β=-0.24)和线索回忆测试(β=-0.40)表现较差相关。

核心结论

  • 血浆p-tau217是唐氏综合征中tau和Aβ脑病理变化的非常准确的血液生物标志物,尤其与年龄联合作为协变量时,可帮助指导未来阿尔茨海默病临床试验的筛查和富集策略。

研究设计与样本

  • 横断面、多中心阿尔茨海默生物标志物联盟-唐氏综合征研究,纳入300例唐氏综合征成人及37例非唐氏综合征同胞对照,参与者于2016年至2019年入组,数据分析时间为2021年8月至2022年4月。

主要发现

  • 在唐氏综合征参与者中,血浆p-tau217和t-tau在Aβ-PET阳性tau-PET阳性(A+T+)及A+T-组较A-T-组显著升高,而GFAP仅在A+T+组升高。
  • A+T+组血浆p-tau217水平显著高于A+T-组。
  • 在年龄协变量模型中,血浆p-tau217和GFAP(而非其他血浆生物标志物)与异常tau-PET和Aβ-PET状态持续相关(OR范围1.59 [95%CI 1.05-2.40] 至2.32 [95%CI 1.36-3.96];P < .03)。
  • p-tau217联合年龄检测颞叶和新皮质区域tau-PET异常表现最佳(AUC范围0.96-0.99);Aβ-PET状态最简约模型包括p-tau217、t-tau和年龄(AUC范围0.93-0.95)。
  • 在多变量模型中,较高p-tau217水平(而非其他生物标志物)与DS精神状况检查(β=-0.24,95%CI -0.36至-0.12;P < .001)和线索回忆测试(β=-0.40,95%CI -0.53至-0.26;P < .001)表现较差相关。

临床怎么用

  • 作者认为血浆p-tau217是唐氏综合征中tau和Aβ脑病理变化的非常准确的血液生物标志物,可帮助指导未来AD临床试验的筛查和富集策略,尤其与年龄联合作为协变量时。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Novel plasma biomarkers, especially phosphorylated tau (p-tau), can detect brain tau aggregates in Alzheimer disease. OBJECTIVE: To determine which plasma biomarker combinations can accurately detect tau pathological brain changes in Down syndrome (DS). DESIGN, SETTING, AND PARTICIPANTS: The cross-sectional, multicenter Alzheimer's Biomarker Consortium-Down Syndrome study included adults with DS and a control group of siblings without DS. All participants with plasma, positron emission tomography (PET), and cognitive measures available by the time of data freeze 1.0 were included. Participants were enrolled between 2016 and 2019, and data were analyzed from August 2021 to April 2022. EXPOSURES: Plasma p-tau217, glial fibrillary acidic protein (GFAP), amyloid β42/40 (Aβ42/Aβ40), neurofilament light (NfL), and total tau (t-tau); tau positron emission tomography (tau-PET) and Aβ-PET. MAIN OUTCOMES AND MEASURES: The primary outcome was tau-PET status. Secondary outcomes included Aβ-PET status and cognitive performance. RESULTS: Among 300 participants with DS and a control group of 37 non-DS siblings, mean (SD) age was 45.0 (10.1) years, and 167 (49.6%) were men. Among participants with DS who all underwent plasma p-tau217 and GFAP analyses, 258 had other plasma biomarker data available and 119, 213, and 288 participants had tau-PET, Aβ-PET, and cognitive assessments, respectively. Plasma p-tau217 and t-tau were significantly increased in Aβ-PET-positive tau-PET-positive (A+T+) DS and A+T- DS compared with A-T- DS while GFAP was only increased in A+T+ DS. Plasma p-tau217 levels were also significantly higher in A+T+ DS than A+T- DS. In participants with DS, plasma p-tau217 and GFAP (but not other plasma biomarkers) were consistently associated with abnormal tau-PET and Aβ-PET status in models covaried for age (odds ratio range, 1.59 [95% CI, 1.05-2.40] to 2.32 [95% CI, 1.36-3.96]; P < .03). A combination of p-tau217 and age performed best when detecting tau-PET abnormality in temporal and neocortical regions (area under the curve [AUC] range, 0.96-0.99). The most parsimonious model for Aβ-PET status included p-tau217, t-tau, and age (AUC range, 0.93-0.95). In multivariable models, higher p-tau217 levels but not other biomarkers were associated with worse performance on DS Mental Status Examination (β, -0.24, 95% CI, -0.36 to -0.12; P < .001) and Cued Recall Test (β, -0.40; 95% CI, -0.53 to -0.26; P < .001). CONCLUSIONS AND RELEVANCE: Plasma p-tau217 is a very accurate blood-based biomarker of both tau and Aβ pathological brain changes in DS that could help guide screening and enrichment strategies for inclusion of individuals with DS in future AD clinical trials, especially when it is combined with age as a covariate.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Janelidze S, Christian BT, Price J, et al. Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers. JAMA Neurol. 2022. PMID: 35789365. doi:10.1001/jamaneurol.2022.1740

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。